RECRUITING

Imaging Biomarkers in Preclinical and Symptomatic AD

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).

Official Title

Imaging Biomarkers in Preclinical and Symptomatic AD. (ACS PiB IND)

Quick Facts

Study Start:2021-06-08
Study Completion:2029-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04134923

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Male or female, any race;
  2. * Age ≥ 18 years;
  3. * Active participants currently enrolled in the Knight Alzheimer's Disease Research Center (ADRC) at Washington University.
  1. * Hypersensitivity to \[11C\] PIB or any of its excipients;
  2. * Contraindications to PET, CT or MRI (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate;
  3. * Severe claustrophobia;
  4. * Women who are pregnant or breast-feeding will be excluded from PIB PET participation;
  5. * Has any condition that, in the opinion of the Sponsor-Investigator or designee could increase risk to the subject, limit the subject's ability to tolerate the research procedures, or interfere with collection of the data;
  6. * Currently participating in any clinical trial which involves an active study medication or placebo within the past 30 days before scanning and up to 2-weeks past the imaging visit.
  7. * Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1

Contacts and Locations

Study Contact

Kelley Jackson
CONTACT
314-297-7602
kelleyj@wustl.edu

Principal Investigator

Tammie Benzinger, MD, PhD
PRINCIPAL_INVESTIGATOR
Washington University School of Medicine

Study Locations (Sites)

Washington University School of Medicine
Saint Louis, Missouri, 63110
United States

Collaborators and Investigators

Sponsor: Tammie L. S. Benzinger, MD, PhD

  • Tammie Benzinger, MD, PhD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-06-08
Study Completion Date2029-10

Study Record Updates

Study Start Date2021-06-08
Study Completion Date2029-10

Terms related to this study

Keywords Provided by Researchers

  • Alzheimer's disease
  • neurology
  • radiology
  • Nuclear medicine

Additional Relevant MeSH Terms

  • Alzheimer Disease